Abstract:Abstract Background Individuals born in 1990 have twice the risk of developing colon cancer and four times the risk of developing rectal cancer as those born in 1950. The gut microbiome is being proposed as a potential contributor to this difference because of the surge in obesity in the United States, the link between obesity and gut dysbiosis, and the growing number of studies which have associated a dysbiotic gut microbiome with CRC. Enterotoxigenic Bacteroides fragilis (ETBF) is one of the bacteria most studied in relation to CRC development; it is found at a higher frequency in both the stool and mucosa of CRC patients, and it rapidly induces tumor formation in an Apcmin/+ mouse model of CRC. In this model, tumor formation typically occurs via loss of heterozygosity (LOH) of the Apc gene, the genetic mutation found in approximately 80% of sporadic CRC cases. ETBF produces a potent exotoxin (BFT) which induces E-cadherin cleavage, β-catenin nuclear localization and colonic epithelial cell proliferation. But we still do not understand how these downstream effects cause lasting changes in the genome of colon epithelial cells that then initiate tumor formation and growth. As cancer is ultimately a disease that arises and progresses via changes in the genome, understanding these interactions is essential. Methods We hypothesize that ETBF induces DNA mutations via BFT that encourage tumor formation, and enhance tumor growth. To test this hypothesis, we performed whole-exome sequencing on tumors and normal tissue isolated from Apcmin/+ mice after ETBF or sham inoculation. Additionally, we isolated colon organoids from Apcmin/+ mouse normal tissue (colonoids) and Apcmin/+ mouse tumors (tumoroids) after ETBF or sham inoculation. We performed in vitro DNA damage assays and qPCR for Apc LOH on these colon organoids. Results Our preliminary data indicate that ETBF-induced tumors have lower rates of Apc LOH and that double-stranded DNA breaks are observed as soon as 3-hours after BFT treatment of colonoids and as soon as 72-hours after ETBF inoculation. Conclusion These data suggest that in vivo, ETBF may induce mutations in cancer-driver genes which cause tumor formation via pathways other than somatic recombination at the Apc locus, a result we are now testing with additional (N = 19) whole-exome tumor sequencing in-progress. Disclosures All authors: No reported disclosures.

Colorectal cancer: role of commensal bacteria and bystander effects

Microbiome-driven carcinogenesis in colorectal cancer: Models and mechanisms

Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment

Colorectal cancer-associated microbiota contributes to oncogenic epigenetic signatures

Influence of the Gut Microbiome, Diet, and Environment on Risk of Colorectal Cancer

Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer

Interaction between microbiota and immunity and its implication in colorectal cancer

Colorectal cancer-associated bacteria are broadly distributed in global microbiomes and drivers of precancerous change

Impact of the gut microbiome on the genome and epigenome of colon epithelial cells: contributions to colorectal cancer development

Gut bacteria, host immunity, and colorectal cancer: From pathogenesis to therapy

Bacterially-Associated Transcriptional Remodelling in a Distinct Genomic Subtype of Colorectal Cancer Provides a Plausible Molecular Basis for Disease Development

Gut microbiota and colorectal cancer: insights into pathogenesis for novel therapeutic strategies

The microbiome and colorectal neoplasia: environmental modifiers of dysbiosis

Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites

2611. Enterotoxigenic Bacteroides fragilis Alters the Genome of Colon Epithelial Cells

Gut Dysbiosis and Abnormal Bile Acid Metabolism in Colitis-Associated Cancer

Gut microbiome: decision-makers in the microenvironment of colorectal cancer

Impact of bacterial infection and intestinal microbiome on colorectal cancer development

The Colloquy between Microbiota and the Immune System in Colon Cancer: Repercussions on the Cancer Therapy

Bacterial translocation and barrier dysfunction enhance colonic tumorigenesis

The Role of the Microbiome in the Etiopathogenesis of Colon Cancer